Provided herein are methods for the efficient in vitro differentiation of somatic cell-derived pluripotent stem cells to hematopoietic precursor cells, and the further differentiation of the hematopoietic precursor cells into immune cells of various myeloid or lymphoid lineages, particularly T cells, NK cells, and dendritic cells. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the hematopoietic precursor cells.

This document provides methods and materials related to differentiating iPS cells into glucose-responsive, insulin-secreting progeny. For example, methods and material for using indolactam V (ILV) and glucagon like peptide-1 (GLP-1) to produce glucose-responsive, insulin-secreting progeny from iPS cells are provided.

Provided herein are methods for the efficient in vitro maintenance, expansion, culture, and/or differentiation of pluripotent cells with disruption of the MeCP2 gene into various erythroid, myeloid, lymphoid, or endoderm lineages, particularly mature erythrocytes. The pluripotent cells may be maintained and differentiated under defined conditions; thus, the use of mouse feeder cells or serum is not required in certain embodiments for the differentiation of the precursor cells.

The present invention provides compositions and methods for reprogramming somatic cells using purified RNA preparations comprising single-strand mRNA encoding an iPS cell induction factor. The purified RNA preparations are preferably substantially free of RNA contaminant molecules that: i) would activate an immune response in the somatic cells, ii) would decrease expression of the single-stranded mRNA in the somatic cells, and/or iii) active RNA sensors in the somatic cells. In certain embodiments, the purified RNA preparations are substantially free of partial mRNAs, double-stranded RNAs, un-capped RNA molecules, and/or single-stranded run-on mRNAs.

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

A method of generating an induced pluripotent stem cell (iPSC) comprises introducing to an animal somatic cell at least one nuclear reprogramming inducing factor and a BRD3R polypeptide or at least one nucleic acid expressing the at least one nuclear reprogramming factor and the BRD3R-related polypeptide in the recipient somatic cell, and culturing said cell to generate an induced pluripotent stem cell (iPSC). The introduction of the BRD3R-related polypeptide into the recipient somatic cell can increase the efficiency of inducing the generation of an iPSC by the at least one nuclear reprogramming inducing factor.

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

A method of generating an induced progenitor population (iPP) of cells and/or induced population of cells from somatic cells, comprising the steps: a) obtaining a starting cell population, wherein cells of the starting cell population comprise, or are contacted with, a nucleic acid molecule encoding four reprogramming factors under the control of a control element, wherein the four reprogramming factors are optionally Oct4, Klf4, Sox2 and c-Myc, and wherein the control element prevents or stops expression of the reprogramming factors under its control in the absence of induction by an inducing agent; and b) transiently inducing expression of the reprogramming factors in the starting cell population to obtain an iPP, c) optionally isolating the iPP, and d) terminating the transient induction while the proliferative capacity of the iPP remains under the control of the one or more exogenous reprogramming factors to produce an induced population of cells.

The present Application is related to methods and compositions for reprogramming adult somatic cells into induced pluripotent stem cells by targeting and remodeling endogenous gene loci without relying on ectopic expression of transcription factors.